Fasting Blood Glucose at Admission and Survival in Patients with Dilated Cardiomyopathy: a Single-center Cohort Study

Abstract

Background: Recent data have suggested that impaired fasting glucose (IFG) is an independent risk factor for mortality in patients with heart failure. However, the prognostic indicator of elevated fasting blood glucose (FBG) such as IFG in dilated cardiomyopathy (DCM) was not well understood. The purpose of this study was to examine the association between IFG at admission and survival in hospitalized patients with DCM.

Methods: A retrospective cohort study was undertaken in 1 089 hospitalized patients with DCM in Fuwai Hospital from November 2003 to September 2 011 (female 26.5%, 51.4±14.6 years old). Standard demographics, echocardiography and routine blood samples were obtained shortly after admission. The outcomes were assessed using all-cause mortality at a mean follow-up of 3.5±2.3 years and were analyzed using Kaplan-Meier survival curve (log-rank test) and Cox regression.

Results: The cohort consisted of 1 089 patients with DCM, 835 patients with normal fasting glucose (NFG, FBG<6.1 mmol/L, 76.7%), 113 patients with IFG (FBG 6.1–6.9 mmol/L, 10.4%), and 141 patients with FBG≥7.0 mmol/L (12.9%). Among the 1 089 patients studied, 252 (23.1%) died over a mean follow-up period of 3.5±2.3 years. All-cause mortality rates were highest in patients with FBG≥7.0 mmol/L (31.2%), intermediate in those with IFG (24.8%), and lowest in those with NFG (21.6%); a significant difference in all-cause mortality rate was found among the 3 groups (log-rank χ²=6.715, P=0.035). After adjustment for baseline variables, New York Heart Association (NYHA) functional class, QRS duration, left atrium diameter, systolic blood pressure, FBG≥7.0 mmol/L, not IFG, and circulating creatinine levels were the variables that remained as predictors of all-cause mortality.

Conclusion: In the present study, all-cause mortality was higher in patients with FBG≥7.0 mmol/L compared to the patients with NFG, and FBG≥ 7.0 mmol/L, not IFG, was one of predictors of all-cause mortality in DCM patients.

Key words

fasting blood glucose - impaired fasting glucose - dilated cardiomyopathy - survival

• References

• 1 Richardson P, McKenna W, Bristow M et al. Report WHOISFCTFDCC. Report, of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93: 841-842
• 2 Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol 1974; 34: 29-34
• 3 MacDonald MR, Petrie MC, Varyani F et al. CHARM Investigators: Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29: 1377-1385
• 4 Domanski M, Krause-Steinrauf H, Deedwania P et al. BEST Investigators: The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003; 42: 914-922
• 5 Shindler DM, Kostis JB, Yusuf S et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996; 77: 1017-1020
• 6 Goode KM, John J, Rigby AS et al. Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart 2009; 95: 917-923
• 7 Berry C, Brett M, Stevenson K et al. Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure. Heart 2008; 94: 296-304
• 8 Gerstein HC, Swedberg K, Carlsson J et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008; 168: 1699-1704
• 9 Kosiborod ML, Inzucchi SE, Spertus JA et al. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. Circulation 2009; 119: 1899-1907
• 10 Barsheshet A, Garty M, Grossman E et al. Admission blood glucose level and mortality among hospitalized nondiabetic patients with heart failure. Arch Intern Med 2006; 14-28 166: 1613-1619
• 11 Maron BJ, Towbin JA, Thiene G et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113: 1807-1816
• 12 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197
• 13 Lang RML, Bierig M, Devereux RB et al. Recommendations for chamber quantification. a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463
• 14 Matsue YL, Suzuki M, Nakamura R et al. Prevalence and prognostic implications of pre-diabetic state in patients with heart failure. Circ J 2011; 75: 2833-2839
• 15 Shimabukuro M, Higa N, Asahi T et al. Impaired glucose tolerance, but not impaired fasting glucose, underlies left ventricular diastolic dysfunction. Diabetes Care 2011; 34: 686-690
• 16 van de Veire NR, de Winter O, Gillebert TC et al. Diabetes and impaired fasting glucose as predictors of morbidity and mortality in male coronary artery disease patients with reduced left ventricular function. Acta Cardiol 2006; 61: 137-143
• 17 DECODE Study Group, the European Diabetes Epidemiology Group . Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405
• 18 Coutinho ML, Gerstein HC, Wang Y et al. The relationship between glucose and incident cardiovascular events: A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240
• 19 Cowie MR, Wood DA, Coats AJ et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000; 83: 505-510
• 20 Lee TT, Chen J, Cohen DJ et al. The association between blood pressure and mortality in patients with heart failure. Am Heart J 2006; 151: 76-83
• 21 Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 2006; 95: 136-147
• 22 Kim J, Nakatani S, Hashimura K et al. Abnormal glucose tolerance contributes to the progression of chronic heart failure in patients with dilated cardiomyopathy. Hypertens Res 2006; 29: 775-782
• 23 Scognamiglio RL, Negut C, De Kreutzenberg SV et al. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 2005; 112: 179-184
• 24 Oswald GA, Smith CC, Betteridge DJ et al. Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. BMJ 1986; 293: 917-922
• 25 Williams SB, Goldfine AB, Timimi FK et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-1701
• 26 Title LM, Cummings PM, Giddens K et al. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardi 2000; 36: 2185-2191
• 27 Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994; 343: 155-158
• 28 Clark RJL, McDonough PM, Swanson E et al. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem 2003; 278: 44230-44237
• 29 Rutter MKL, Parise H, Benjamin EJ et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003; 107: 448-454
• 30 Gulati AL, Jabbour A, Ismail TF et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 2013; 309: 896-908
• 31 Passino CL, Pingitore A, Landi P et al. Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure. J Card Fail 2009; 15: 35-40
• 32 Sandhu R, Bahler RC. Prevalence of QRS prolongation in a community hospital cohort of patients with heart failure and its relation to left ventricular systolic dysfunction. Am J Cardiol 2004; 93: 244-246
• 33 Cheng SL, Larson MG, Keyes MJ et al. Relation of QRS width in healthy persons to risk of future permanent pacemaker implantation. Am J Cardiol 2010; 106: 668-672
• 34 Eriksson P, Hansson PO, Eriksson H et al. Prognostic significance of incident complete left bundle branch block observed over a 40-year period. Am J Cardiol 2006; 98: 644-648
• 35 Xiao HB, Roy C, Fujimoto S et al. Natural history of abnormal conduction and its relation to prognosis in patients with dilated cardiomyopathy. Int J Cardiol 1996; 53: 163-170
• 36 Lund LHL, Jurga J, Edner M et al. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J 2013; 34: 529-539
• 37 O’Connor CM, Abraham WT, Albert NM et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008; 156: 662-673
• 38 Bocchi EA, Arias A, Verdejo H et al. The reality of heart failure in Latin America. J Am Coll Cardio 2013; 62: 949-958